A newly funded effort around RNA editing uses human Argonaute 2 to build a programmable RNA base editor, with early framing focused on reducing immune-risk concerns tied to non-human components. The approach, reported in Nature Biotechnology, positions ALTER as a human-protein-only editing tool. On the manufacturing side, Thermo Fisher’s analysis argues that there is no universally best rAAV vector production platform; transient transfection, producer cell line processes, and baculovirus approaches have different cost fingerprints once normalized to titer and vector requirements. For CDMOs and sponsors, the message is that patient population and clinical plan should drive the manufacturing choice. Together, the updates reinforce that therapeutic feasibility now depends as much on platform selection and immunological risk management as on the editing chemistry itself.